You can buy or sell UBX and other stocks, options, ETFs, and crypto commission-free!
Unity Biotechnology, Inc. operates as a biotechnology company engaged in the research and development of therapeutics to extend the human health span. The company was founded by Nathaniel David, Jan van Deursen, Judith Campisi and Daohong Zhou in March 2009 and is headquartered in Brisbane, CA.
52 Week High
52 Week Low
Research And Development
Seeking AlphaMar 7
Cantor likes Unity Biotech, shares up 15% premarket
Thinly traded micro cap Unity Biotechnology (NASDAQ:UBX) is up 15% premarket, albeit on only 641 shares, on the heels of new coverage by Cantor Fitzgerald.
Associated PressMar 4
UNITY Biotechnology, Inc. to Participate in the Cowen 39th Annual Health Care Conference
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. SAN FRANCISCO, March 04, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today...
Stock Price, News, & Analysis for Unity Biotechnology
Unity Biotechnology, Inc., a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was foun...
Expected Jun 6, Pre-Market